Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
October 13 2020 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical
company focused on discovering and developing novel products to
treat cancer, today announced that Dr. Steven M. Fruchtman,
President and Chief Executive Officer, will present a company
update during the 2020 BIO Investor Forum Digital event taking
place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP,
Corporate Development, will be available for 1x1 meetings scheduled
through the Bio Partnering system.
The Presentation will be available On Demand for event
participants October 13-15 and at
https://investor.onconova.com/events-and-presentations as of
October 15th.
About Onconova Therapeutics,
Inc.Onconova Therapeutics is a biopharmaceutical company
focused on discovering and developing novel products to treat
cancer. The Company has proprietary targeted anti-cancer agents
designed to disrupt specific cellular pathways that are important
for cancer cell proliferation. Onconova is in preclinical
development with its novel, proprietary, CDK4/6 + ARK5 inhibitor,
ON 123300. Onconova’s RAS pathway inhibitor, oral
rigosertib, is currently in a Phase 1/2 investigator-initiated
study (IIS) targeting patients with KRAS+ lung adenocarcinoma in
combination with nivolumab. Preclinical work with rigosertib in
COVID-19 is underway as well.
For more information, please visit
https://www.onconova.com.
Forward-Looking StatementsSome
of the statements in this release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
and involve risks and uncertainties. These statements relate to
Onconova expectations regarding its clinical development plans and
patents. Onconova has attempted to identify forward-looking
statements by terminology including "believes," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes. Although Onconova
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including the success and timing
of Onconova's clinical trials and regulatory approval of protocols,
Onconova’s ability to continue as a going concern, the need for
additional financing, our collaborations, and those discussed under
the heading "Risk Factors" in Onconova's most recent Annual Report
on Form 10-K and quarterly reports on Form 10-Q. Any
forward-looking statements contained in this release speak only as
of its date. Onconova undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Press release contact
information
Company Contact:
Avi OlerOnconova Therapeutics, Inc.267-759-3680
ir@onconova.ushttps://www.onconova.com/contact/
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024